報價延遲最少15分鐘:2025/11/15 16:12 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.61/-1.64
|
|
企業價值
45.13M
|
| 資產負債 |
|
每股賬面淨值
0.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 16:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. |
